Compare Novartis AG (NVS) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Payoneer Global Inc — how do they compare? Novartis AG trades at $152.8 (market cap $295.37B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Novartis AG is far larger — about 123.1× Payoneer Global Inc's market cap, and Novartis AG pays a 3.07% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| NVS | PAYO | |
|---|---|---|
Market Cap | $295.37B | $2.40B |
Sector | Health | Technology |
52-Week High | $168.62 | $7.17 |
52-Week Low | $119.31 | $4.27 |
Enterprise Value | $336.69B | $2.14B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Payoneer Global Inc. (PAYO) trades at $7.09, down 0.14% on the day, near its 52-week high of $7.67. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal mixed earnings with Q2 2026 EPS missing estimates at $0.02 versus $0.06 expected. Revenue growth remains solid, up 10% year-over-year excluding interest in Q2 2026. Sentiment is influenced by the pending acquisition by Nuvei for $7.40 per share, announced on June 15, 2026, which has sparked legal inquiries over fairness.
The outlook is cautiously optimistic with a consensus price target of $8.20 offering 16% upside, but risks include integration challenges from the Nuvei deal and earnings volatility. Investors should weigh the acquisition premium against potential shareholder litigation and execution risks in cross-border payment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
